Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immucell (ICCC) Total Liabilities (2016 - 2025)

Immucell's Total Liabilities history spans 16 years, with the latest figure at $15.5 million for Q4 2025.

  • For Q4 2025, Total Liabilities fell 11.97% year-over-year to $15.5 million; the TTM value through Dec 2025 reached $15.5 million, down 11.97%, while the annual FY2025 figure was $15.5 million, 11.97% down from the prior year.
  • Total Liabilities reached $15.5 million in Q4 2025 per ICCC's latest filing, down from $15.9 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $18.8 million in Q4 2023 to a low of $11.5 million in Q2 2021.
  • Average Total Liabilities over 5 years is $15.5 million, with a median of $15.7 million recorded in 2025.
  • Peak YoY movement for Total Liabilities: grew 29.93% in 2023, then decreased 11.97% in 2025.
  • A 5-year view of Total Liabilities shows it stood at $11.9 million in 2021, then rose by 21.8% to $14.5 million in 2022, then rose by 29.93% to $18.8 million in 2023, then decreased by 6.55% to $17.6 million in 2024, then decreased by 11.97% to $15.5 million in 2025.
  • Per Business Quant, the three most recent readings for ICCC's Total Liabilities are $15.5 million (Q4 2025), $15.9 million (Q3 2025), and $16.9 million (Q2 2025).